Search

Author/Creator Armand, P.

1. A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). (June 2017)

Authors:
Caimi, P.F.; Eder, J.P.; Jacobsen, E.D.; Jacobson, C.A.; LaCasce, A.S.; Shipp, M.A.; Chapuy, B.; Labriola‐Tomphins, E.; Boisserie, F.; Passe, S.; Chesné, E.; Pierceall, W.; Zhi, J.; DeMario, M.; Vaishampayan, U.; Dowlati, A.; Shapiro, G.I.; Fisher, D.C.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
263
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. (June 2017)

Authors:
Zinzani, P.; Thieblemont, C.; Melnichenko, V.; Osmanov, D.; Bouabdallah, K.; Walewski, J.; Majlis, A.; Fogliatto, L.; Caballero Barrigón, M.D.; Christian, B.; Gulbas, Z.; Özcan, M.; Salles, G.A.; Shipp, M.A.; Balakumaran, A.; Chlosta, S.; Chatterjee, A.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
62
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE. (12th June 2019)

Authors:
Ansell, S.M.; Bartlett, N.L.; Chen, R.W.; Herrera, A.; Domingo‐Domenech, E.; Mehta, A.; Forero‐Torres, A.; Garcia‐Sanz, R.; Armand, P.; Devata, S.; Rodriguez Izquierdo, A.; Lossos, I.S.; Reeder, C.B.; Sher, T.; Choe‐Juliak, C.; Prier, K.; Schwarz, S.E.; Strassz, A.; Alland, L.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
177
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. (17th June 2021)

Authors:
Ansell, S. M.; Bröckelmann, P. J.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G. P.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; Provencio, M.; Jaeger, U.; Willenbacher, W.; Swanink, R.; Sacchi, M.; Shipp, M. A.; Engert, A.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL. (June 2017)

Authors:
Fanale, M.; Engert, A.; Younes, A.; Armand, P.; Ansell, S.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; De Boer, J.P.; Kuruvilla, J.; Savage, K.J.; Trneny, M.; Rodig, S.; Shipp, M.; Kato, K.; Sumbul, A.; Farsaci, B.; Santoro, A.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP. (12th June 2019)

Authors:
Ansell, S.; Ramchandren, R.; Domingo‐Domènech, E.; Rueda, A.; Trněný, M.; Feldman, T.; Lee, H.; Provencio, M.; Sillaber, C.; Cohen, J.; Savage, K.; Willenbacher, W.; Sumbul, A.; Sacchi, M.; Armand, P.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022)

Authors:
Gregory, G.; Timmerman, J.; Lavie, D.; Borchmann, P.; Herrera, A. F.; Minuk, L.; Vucinic, V.; Armand, P.; Avigdor, A.; Gasiorowski, R.; Herishanu, Y.; Keane, C.; Kuruvilla, J.; Palcza, J.; Pillai, P.; Marinello, P.; Johnson, N. A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
976
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗